Comparability of the Reference Drug Pulmozim and a Similar Drug Tigerase in Terms of their Pharmacodynamic, Toxicological and Pharmacokinetic Properties

This work presents research studies into the comparability of Tigerase® (inhalation solution, manufactured by JSC «GENERIUM», Russia) to the reference drug Pulmozim® (inhalation solution, manufactured by Hoffmann-La Roche Ltd., Switzerland). Both drugs contain human recombinant deoxyribonuclease I – dornase alpha as an active substance and are intended for the treatment of cystic fibrosis with pulmonary manifestations (cystic fibrosis). The specific enzymatic activity of dornase alpha was studied in vitro and ex vivo using samples of patients’ purulent sputum. The pharmacokinetic parameters of the drugs were studied in the blood serum, bronchi and lungs. The main physiological parameters (body weight and temperature, the state of the cardiovascular, respiratory, excretory systems, hematological and biochemical blood parameters, pathomorphological changes in the internal organs, including the state of the cornea of the eyes, mortality rates) were assessed in comparative studies of subchronic toxicity in juvenile and sexually mature rats using 28-day inhalation in doses of 0.2 mg/kg to sexually mature and 0.26 mg/kg to juvenile animals (the dose was 6 times higher than the recommended dose for clinical use). It was concluded that the drugs were comparable in terms of their enzymatic, mucolytic (secretolytic) DNase activity, safety profile, and basic pharmacokinetic parameters.

1. Avdeeva O.E., Avdeev S.N., Tchuchalin A.G. Ekzogenniy allergitceskii alveolit [Exogenous allergic alveolitis]. Russian medical journal. 1997;17:6. (In Russian).

2. Eltsova E.A., Ramenskaia G.V., Smoliartshuk E.A., Bushmanova A.V. Biosimilari – preparati budushchego [Biosimilars are the drugs of the future]. Pharmacokinetics and pharmacodynamics. 2015;1:12-15. (In Russian).

3. Cystic fibrosis. Clinical recommendation. Union of Pediatricians of Russia, Association of Pregnant Geneticists, Russian Respiratory Society, Russian Transplant Society, Association of Children's Doctors of the Moscow Region, 2021. (In Russian). URL: https://mukoviscidoz.org/ doc/%D0%9A%D0%A0372.pdf

4. Kolbin A.S., Gomon Ju.M., Karpov O.I., Balikina Ju.E., Proskurin M.A. Mukovistsidoz kak sotsialno-ekonomitcheskaia problema [Cystic fibrosis as economic social problem]. Kachestvennaia klinitcheskaia praktika [Good clinical practice]. 2020;5:38-49. (In Russian). DOI: 10.37489/2588-0519-2020-5-38-49.

5. Kosarev V.V., Babanov S.A. Ekzogenniy allergitceskii alveolit: problemi diagnostiki [Exogenous allergic alveolitis: problems in diagnosis]. Russian medical journal. 2013;7:388-392. (In Russian).

6. Mezhdunarodnaia klassifikatsia boleznei 10-go peresmotra (MKB-10) [International Statistical Classification of Diseases and Related Health Problems ICD-10 Updates (ICD10)]. (In Russian).

7. Register of patients with cystic fibrosis in the Russian Federation]. 2019. (In Russian). URL: https://mukoviscidoz.org/doc/registr/ site_Registre_2019.pdf

8. Cooney A.L., McCray P.B. Jr., Sinn P.L. Cystic fibrosis gene therapy: Looking back, looking forward. Genes (Basel). 2018;9(11):538–561. DOI: 10.3390/ genes9110538.

9. Dayan A.D. Pharmacological-toxicological (Expert report on recombinant human Deoxyribonuclease I (rhDNase; PulmozymeTM). Hum. Exper. Toxicology. 1994;13:S2–S42. DOI: 10.1177/096032719401300101.

10. Dechecchi M.C., Tamanini A., Cabrini G. Molecular basis of cystic fibrosis: From bench to bedside. Ann. Transl. Med. 2018;6(17):334. DOI: 10.21037/ atm.2018.06.48.

11. Eisenberg J.D., Aitken M.L., Dorkin H.L., Harwood I.R., Ramsey B.W., Schidlow D.V., Wilmott R.W., Wohl M.E., Fuchs H.J., Christiansen D.H., Smith A.L. Safety of repeated intermittent courses of aerosolized recombinant human deoxyribonuclease in patients with cystic fibrosis. J. Pediatr. 1997;131(1 Pt 1):118– 124. DOI: 10.1016/s0022-3476(97)70134-3.

12. El-Bakry L. The future of biosimilars. Int. J. Drug Delivery. 2017;9:01–02. DOI: 10.5138/09750215.1930.

13. Guideline on bioanalytical method validation. EMEA/ CHMP/EWP/192217/2009 Rev. 1 Corr. 2. European Medicines Agency, Committee for Medicinal Products for Human Use, 2011. URL: https://www. ema.europa.eu/en/documents/scientific-guideline/ guideline-bioanalytical-method-validation_en.pdf.

14. Farfan-Portet M-I., Gerkens S., Lepage-Nefkens I., Vinck I., Hulstaert F. Are biosimilars the next tool to guarantee cost-containment for pharmaceutical expenditures? Eur. J. Health Econ. 2014;15(3):223–228. DOI: 10.1007/s10198-013-0538-4.

15. Guideline on similar biological medicinal products containing biotechnology-derived proteins as active substance: quality issues (revision 1). EMA/CHMP/ BWP/247713/2012. European Medicines Agency, Committee for Medicinal Products for Human Use, 2014. URL: https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-similar-biological-medicinal-products-containing-biotechnology-derived-proteins-active_en-0.pdf.

16. Guideline on similar biological medicinal products containing monoclonal antibodies – non-clinical and clinical issues. CHMP/BMWP/403543/2010, European Medicines Agency, Committee for Medicinal Products for Human Use, 2012. URL: https://www. ema.europa.eu/en/documents/scientific-guideline/ guideline-similar-biological-medicinal-productscontaining-monoclonal-antibodies-non-clinical_en.pdf.

17. Guideline on similar biological medicinal products containing biotechnology-derived proteins as drug substance: non-clinical and clinical issues. EMEA/CHMP/BMWP/42832/2005 Rev 1, European Medicines Agency, Committee for Medicinal Products for Human Use, 2014. URL: https://www.ema.europa. eu/en/documents/scientific-guideline/guideline-similar-biological-medicinal-products-containing-biotechnology-derived-proteins-active_en-2.pdf.

18. Hodson M.E. Aerosolized dornase alfa (rhDNase) for therapy of cystic fibrosis. Am. J. Respir. Crit. Care Med. 1995;151(3 Pt 2):S70–S74. DOI: 10.1164/ajrccm/151.3_Pt_2.S70.

19. Honavar S.G. From biologics to biosimilars and biobetters — democratization of high-end therapeutics. Indian J. Ophthalmol. 2021;69(2):207–208. DOI: 10.4103/ijo.IJO_150_21.

20. Semaniakou A., Croll R.P., Chappe V. Animal models in the pathophysiology of cystic fibrosis. Front Pharmacol. 2018;9:1475. DOI: 10.3389/ fphar.2018.01475.

21. Shankar G., Devanarayan V., Amaravadi L., BarrettY.C., Bowsher R., Finco-Kent D., Fiscella M., Gorovits B., Kirschner S., Moxness M., Parish T., Quarmby V., Smith H., Smith W., Zuckerman L.A., Koren E. Recommendations for the validation of immunoassays used for detection of host antibodies against biotechnology products. J. Pharm. Biomed. Anal. 2008;48(5):1267– 1281. DOI: 10.1016/j.jpba.2008.09.020.

22. Welsh M.J., Smith A.E. Molecular mechanism of CFTR chloride channel dysfunction in cystic fibrosis. Cell. 1993;73(7):1251–1254. DOI: 10.1016/0092- 8674(93)90353-r.